AI Summary
Scientists have developed a smaller CRISPR-based gene-editing tool, AsCas12f, that could improve treatments for genetic disorders by delivering more of it into living cells.
A new CRISPR-based gene-editing tool has been developed which could lead to better treatments for patients with genetic disorders. The tool is an enzyme, AsCas12f, which has been modified to offer the same effectiveness but at one-third the size of the Cas9 enzyme commonly used for gene editing. The compact size means that more of it can be packed into carrier viruses and delivered into living cells, making it more efficient.